These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

A scientific report has raised doubts about the real-world effectiveness of Leqimbi and Kisunla, two recently launched Alzheimer’s drugs. The article suggests they may slow disease progression less than originally implied, which is a modest negative for sentiment around the therapies and their broader commercial outlook. The likely market impact is limited but could pressure expectations for adoption and future sales growth.

Analysis

A scientific report has raised doubts about the real-world effectiveness of Leqimbi and Kisunla, two recently launched Alzheimer’s drugs. The article suggests they may slow disease progression less than originally implied, which is a modest negative for sentiment around the therapies and their broader commercial outlook. The likely market impact is limited but could pressure expectations for adoption and future sales growth.